Featured Research

from universities, journals, and other organizations

Molecular Traffic Signal Could Be New HIV Drug Target

Date:
December 9, 1999
Source:
National Institute Of Allergy And Infectious Diseases
Summary:
A single HIV protein acts as a molecular traffic signal to regulate crucial steps in the virus' life cycle, a new study has found. The discovery of these previously unrecognized stop-and-go functions provides new targets for creating molecular gridlock and halting virus growth.

A single HIV protein acts as a molecular traffic signal to regulate crucial steps in the virus' life cycle, a new study has found. The discovery of these previously unrecognized stop-and-go functions provides new targets for creating molecular gridlock and halting virus growth. A research team led by Michael R. Green, M.D., Ph.D., and Mario Stevenson, Ph.D., of the University of Massachusetts Medical Center in Worcester, reports the findings in the Dec. 9, 1999 issue of Nature.

Related Articles


"This study helps fill in a missing piece of the HIV reproduction process," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), which funded the study. "The findings suggest we may be able to devise therapies that subvert the order and timing of cellular events necessary for HIV replication."

By systematically analyzing the properties of normal and mutant forms of HIV, Drs. Green, Stevenson and their colleagues found that a molecule known as HIV matrix protein, an important building block within HIV's core, controls two opposing functions. Each function comes into play during a different stage in the HIV infection cycle.

For HIV to reproduce inside human cells, it must first invade the nucleus and commandeer the cell's genetic machinery. "Early after HIV infection, matrix protein helps import HIV genetic material into the nucleus of the infected cell," says Dr. Green. Once inside the nucleus, HIV co-opts the genetic machinery to churn out copies of the virus' genetic material, called RNA. That viral RNA then forms the genetic blueprints from which new HIV proteins are constructed.

Later in the infection cycle, the matrix protein reverses the flow of traffic and directs new HIV proteins away from the nucleus and into the surrounding cell cytoplasm where new viruses are assembled and packaged.

"How matrix protein suddenly reverses course has been a mystery," says Dr. Green. "Our study shows that the nuclear export signal kicks in late after infection."

"These data confirm what other studies have suggested - that matrix protein helps localize HIV genetic material to the cell nucleus so that integration and transcription can take place," notes Nava Sarver, Ph.D., chief of the targeted interventions branch in NIAID's Division of AIDS. "The evidence that the matrix protein also has a nuclear export activity required for viral replication is exciting new information.

"The opposing functions of the HIV matrix protein represent two new discrete targets for anti-HIV drugs," adds Dr. Sarver. "Drugs designed to block either the import or export signals can undermine the carefully orchestrated course of events during HIV replication, and could shut down the growth of the virus."

NIAID is a component of the National Institutes of Health (NIH). NIAID conducts and supports research to prevent, diagnose and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, malaria, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services. The Howard Hughes Medical Institute also provided support for this study.

###

Reference:
S Dupont, N Sharova, C DeHoratius, C-MA Virbasius, X Zhu, AG Bukrinskaya, M Stevenson and MR Green. A novel nuclear export activity in HIV-1 matrix protein required for viral replication. Nature 402:681-85 (1999).

Press releases, fact sheets and other NIAID-related materials are available on the NIAID web site at http://www.niaid.nih.gov .


Story Source:

The above story is based on materials provided by National Institute Of Allergy And Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

National Institute Of Allergy And Infectious Diseases. "Molecular Traffic Signal Could Be New HIV Drug Target." ScienceDaily. ScienceDaily, 9 December 1999. <www.sciencedaily.com/releases/1999/12/991209045121.htm>.
National Institute Of Allergy And Infectious Diseases. (1999, December 9). Molecular Traffic Signal Could Be New HIV Drug Target. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/1999/12/991209045121.htm
National Institute Of Allergy And Infectious Diseases. "Molecular Traffic Signal Could Be New HIV Drug Target." ScienceDaily. www.sciencedaily.com/releases/1999/12/991209045121.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins